The Vendor Status Tracker is a page on Amino Axiom, a free research information platform that also hosts a compound library, a vendor directory, price comparison, a glossary and a keyword search. The tracker is the part of the vendor directory that records which research peptide vendors are defunct, why they stopped operating, and how that sits against the timeline of FDA enforcement activity in the research chemical space. It lives at the Vendor Status Tracker.
It is a record, not a recommendation engine. The page lists what has happened to named vendors and when. It does not rank sources, and it makes no claim about the quality of any compound. For a laboratory, the value is simple: supply-chain history is a variable in an experiment, and this page puts that history in one place.
Why does vendor status matter for incretin research?
Incretin-class peptides are some of the most demanding materials to source for bench work. Native GLP-1 is a 30-residue hormone whose catalog entry lists a molecular weight of 3337.73 g/mol and a formula of C151H226N40O46. Lipidated analogs such as GLP-1(S) carry a fatty di-acid side chain and a different mass, listed at 4113.58 g/mol with a formula of C187H291N45O59. Each of these is a long synthetic molecule with real opportunities for truncation products, oxidation, aggregation and incomplete lipidation during manufacture.
A receptor pharmacology program that benchmarks ligands in cAMP functional assays needs the same material, with the same identity and purity profile, across many months. If the vendor behind a reference lot disappears, the lab loses the ability to re-order a matching lot, to ask for supporting analytical records, or to trace a discrepancy back to its origin. A tracker that records which vendors have gone defunct gives a researcher an early signal about continuity risk before a long study is built on a single source.
What does the tracker actually show?
The page is organized around individual vendors. For each entry a researcher can expect to see the vendor name, its current status, a short explanation of why the status changed, and a position on a timeline. The status categories describe the practical state of the vendor, for example whether it is still operating or has ceased operations. The explanation field is where the page records the stated or documented reason, such as regulatory action, a payment processing loss, or a voluntary shutdown.
The timeline element places those events next to the public chronology of FDA enforcement in this area. Reading the two together lets a researcher see whether a cluster of closures followed a specific enforcement event or accumulated gradually. That distinction matters when estimating how stable the remaining supply base is, because a single event suggests a one-time shock, while a steady drip suggests structural pressure.
Everything on the page is descriptive. A researcher still has to confirm any detail against primary sources, since the tracker summarizes public information and does not replace a direct inquiry to a supplier.
How would an incretin lab read an entry?
Take a hypothetical study comparing native GLP-1 with a lipidated analog in a receptor internalization assay. The study design depends on three material questions: is the identity confirmed, is the purity documented, and can the same lot or an equivalent one be obtained again. The tracker speaks to the third.
A practical reading sequence looks like this:
Find the vendor in the directory and open its status entry.
Note the status and the date it changed. A recent change deserves more attention than an old one, because lots purchased before the change may be the last of their kind.
Read the stated reason. Regulatory reasons imply a different kind of risk than a voluntary closure.
Check where the date falls on the enforcement timeline and whether other vendors changed status at the same time.
Cross-check the compound pages for the molecules in question, such as the entries for GLP-1 and GLP-1(S), against the catalog identifiers the lab already holds.
None of these steps requires any claim about what the compound does in a living system. They are bookkeeping steps about a supply chain, which is exactly where reproducibility problems often begin.
Which compounds are most exposed to supply discontinuity?
Complex multi-receptor agonists tend to have fewer qualified manufacturers than simple peptides. Retatrutide-class GLP-3(R), listed in the catalog with a molecular weight of 4731.33 g/mol and a formula of C221H342N46O68, is a triple receptor agonist with a lipidated scaffold. Dual and triple agonist research tools are newer, and the number of laboratories able to synthesize and verify them is smaller than for the older single-target reference peptides.
That has a direct consequence for how a lab reads vendor status. If a vendor that supplied one of these newer scaffolds appears in the defunct list, the realistic set of replacement sources is narrower. A lab running a multi-receptor comparison may need to re-qualify a new source, repeat identity confirmation by mass spectrometry, and bridge the old and new lots in a side-by-side assay before data from the two periods can be combined.
For the older reference molecules the pool of sources is broader, but the same logic applies in a weaker form. Lot-to-lot bridging is a standard control in any program that spans a long period.
How does vendor history connect to analytical documentation?
Published research practice treats a certificate of analysis and an independent identity check as separate things. A certificate describes what the supplier measured. An independent check, such as intact mass by liquid chromatography and mass spectrometry, describes what the receiving lab measured. The catalog identifiers for each compound, including molecular weight and formula, provide the expected values for that second check. For example, the listed molecular weight of 3337.73 g/mol for native GLP-1 is the target a deconvoluted mass spectrum should match, within the instrument's tolerance.
When a vendor is listed as defunct, the practical loss is often the ability to ask follow-up questions about a lot: the synthesis route, the counterion, the lyophilization conditions, the retained sample. The tracker does not restore that access, but it helps a researcher decide, before purchasing, whether a source is likely to be around to answer such questions.
What are the limits of a status tracker?
A tracker has three limits worth stating plainly.
First, it is a snapshot. Status can change, and a page can lag behind events. A researcher relying on it for a decision should note the date it was last updated.
Second, it summarizes public information. It cannot see private quality problems at an operating vendor, and an operating status is not an endorsement of material quality.
Third, it says nothing about the science. Whether a compound engages a receptor, and with what selectivity, is answered by the published pharmacology literature and by the lab's own assays, not by a directory.
Used within those limits, the page is one input among several. The others are the lab's own analytical results, the published characterization of the molecule, and direct correspondence with suppliers.
Where does this fit in a research workflow?
A reasonable place for the tracker is at the planning stage of a study, before material is purchased. A lab can list the compounds it needs, check the status of each candidate source, and record the result in its project notes next to the expected identifiers. If the study will run for many months, the lab can plan lot reserves or a bridging experiment up front instead of discovering the problem mid-study.
Amino Axiom also offers a compound library and a comparison tool that sit alongside the directory, and the platform's homepage at Amino Axiom gives an overview of what is available. For the purposes of this article the relevant surface is the tracker itself, and the walkthrough above is intended to show how its entries can be read as supply-chain context for incretin work.
Research use disclaimer
All compounds referenced in this article are supplied for laboratory research use only. They are not intended for human or veterinary use, and nothing here describes or implies any use outside in vitro and other controlled research settings. Descriptions of Amino Axiom reflect only what its Vendor Status Tracker page visibly presents. For research purposes only.
